ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Shionogi as a shareholder, today announced data to be presented this week at the 26 th International AIDS Conference ...

Following in the footsteps of Gilead Sciences, Merck & Co. has signed voluntary licensing agreements to enable access to its ...

Merck has announced an early global access plan for Alimatravir, an experimental once-monthly pill being developed to prevent ...

On Tuesday, the White House Office of Science and Technology Policy (OSTP) released a report entitled “Science: A New Golden ...

Planning early for rapid, broad and sustainable access in LMICs : By initiating a multi-faceted access strategy while Phase 3 trials are ongoing and before enrollment is complete, Merck aims to make ...

For the first time, Merck has granted generic manufacturers, including three African companies, permission to produce an ...

Researchers have mapped DNA methylation and 3D genome contacts in the same cells. The atlas uncovers cell-type-specific ...

PEPFAR cuts left 77,163 fewer children on HIV treatment in FY2025, a 14.2% global decline, as peer-reviewed studies at the ...

Most advisor AI competes on hours saved. Continuum's founders came to a different conclusion after experiencing advice from the client's side of the table ...

A recent study from Washtenaw Optimal Wellness is shedding new light on a long-standing reality in Ypsilanti: where residents ...

Alkane Resources Limited (ASX: ALK; TSX: ALK; OTCQX: ALKRY) ("Alkane" or "the Company") is pleased to announce the latest ...

Specialized cells in the human body make biological trade-offs to perform certain jobs. To support the large, hardworking hearts that power other organs, heart cells have evolved to be extremely ...